mtm laboratories Inc. Launches Cervatec(TM) Assay for Cervical Cancer Screening

HEIDELBERG, Germany--(BUSINESS WIRE)--mtm laboratories today announced the launch of the CE-labelled Cervatecâ„¢ Assay and, at the same time, the results from a large prospective study demonstrating substantially superior sensitivity to the presence of disease over Pap test alone. The Cervatecâ„¢ ELISA assay will initially be commercialized in Central Europe as an adjunct to the Pap Test in screening of women aged 35 and younger.

Back to news